Entera Bio Ltd
Company Profile
Business description
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
Contact
Minrav Building - Fifth Floor
Kiryat Hadassah
Jerusalem9112002
ISRT: +972 25327151
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
20
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,365.70 | 24.70 | 0.30% |
CAC 40 | 7,593.87 | 38.00 | 0.50% |
DAX 40 | 22,496.98 | 71.15 | 0.32% |
Dow JONES (US) | 40,669.36 | 141.74 | 0.35% |
FTSE 100 | 8,496.58 | 1.73 | 0.02% |
HKSE | 22,119.41 | 111.30 | 0.51% |
NASDAQ | 17,446.34 | 14.98 | -0.09% |
Nikkei 225 | 36,452.30 | 406.92 | 1.13% |
NZX 50 Index | 12,148.60 | 245.29 | 2.06% |
S&P 500 | 5,569.06 | 8.23 | 0.15% |
S&P/ASX 200 | 8,145.60 | 19.40 | 0.24% |
SSE Composite Index | 3,279.03 | 7.62 | -0.23% |